Multi-center Study to Evaluate the Efficacy and Safety of Maintenance Therapy With Valrubicin Versus no Maintenance, in Subjects Treated With Valrubicin Induction for Carcinoma in Situ (CIS) of the Bladder

Clinical trial NCT01310803 · TERMINATED

Trial details

NCT number

NCT01310803

Sponsor

Endo USA Inc., a Keenova Therapeutics Company

Status

TERMINATED

Phase

Phase 3

Study type

INTERVENTIONAL

Start date

2011-05-01

Primary completion

2012-01-01

Enrollment

1

View on ClinicalTrials.gov